For research and educational purposes only. Not medical advice.
IGF-1 LR3 Reference
Educational, not medical advice reference for IGF-1 LR3: Growth Factor; regulatory status, evidence posture, source review, and schedule notes.…
Reference summary
IGF-1 LR3 was developed primarily as a cell-culture research reagent, not as a human therapeutic. There is no published human clinical program for long-R3 IGF-1 as a research peptide. Community framing extrapolates from recombinant IGF-1 pharmacology.
Regulatory and posture
- Categories
- Growth Factor
- Aliases
- Long R3 IGF-1, Long-R3 IGF-1, Recombinant long-R3 IGF-1
- Evidence posture
- preclinical - WADA-prohibited. No published human clinical program for IGF-1 LR3 as a research peptide. Hypoglycemia, tissue overgrowth, and anti-doping sanction are the principal documented risks.
- Regulatory status
- No FDA-approved IGF-1 LR3 drug label. IGF-1 LR3 is a modified recombinant IGF-1 analog used in cell-culture research and sold in gray-market research-vial form. WADA prohibits IGF-1 and its analogs under category S2 (peptide hormones, growth factors, related substances, and mimetics) at all times, in and out of competition.
- Content review status
- research reference
Selected public sources
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.